Abbott Laboratories

Abbott Laboratories(ABT)の株式分析

$102.970

+0.360 (+0.35%)終値時点

Loading chart…
高値
104.060
始値
104.060
出来高加重平均価格
102.91
出来高
7.29M
時価総額
182.05B
安値
101.690
売買代金
749.85M
EV/EBITDA(TTM)
18.07

Abbott Laboratories is a global healthcare company. The Company’s principal business is the discovery, development, manufacture, and sale of a broad and diversified line of healthcare products. Its segments include Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. Established Pharmaceutical Products segment is engaged in the international sales of a broad line of branded generic pharmaceutical products. Diagnostic Products segment is involved in the worldwide sales of diagnostic systems and tests for blood banks, hospitals, commercial laboratories and alternate-care testing sites. Nutritional Products segment is engaged in the worldwide sales of a broad line of adult and pediatric nutritional products. Medical Devices segment is involved in the worldwide sales of rhythm management, electrophysiology, heart failure, vascular, structural heart, neuromodulation and diabetes care products. It serves people in more than 160 countries.

www.abbott.com

AI分析 of Abbott Laboratories (ABT)

買い

Abbott Laboratories is a good buy right now due to its current price of $99.60, which is significantly below the analyst price targets ranging from $120 to $127. The forward P/E ratio is 17.094, indicating potential for growth compared to its current valuation. Additionally, the recent product launch of Ensure Max Protein is expected to drive revenue growth, while the RSI of 50.277 suggests the stock is neither overbought nor oversold, making it a favorable entry point.

アナリスト評価(20)

上値余地 +43.84%
買い
13 買い
7 中立
0 売り
現在: 102.97
安値
136.00
平均
148.11
高値
169.00

Barclays

2026-10-06

目標株価

$120

オーバーウェイト

Rothschild & Co Redburn

2026-10-02

目標株価

$127

買い

Citi

2026-08-13

目標株価

$125

買い

Wolfe Research

2026-08-13

目標株価

$130

アウトパフォーム

UBS

2026-07-28

目標株価

$125

買い

バリュエーション指標

Abbott Laboratories(ABT)の現在の予想PERは17.09で、5年平均は23.51です。

予想PER

大幅な割安
5年平均 P/E
23.51
現在のP/E
17.09
割高
26.30
割安
20.73

予想EV/EBITDA

適正
5年平均 EV/EBITDA
18.33
現在のEV/EBITDA
18.07
割高
20.01
割安
16.66

予想PSR

割安
5年平均 P/S
4.50
現在のP/S
3.26
割高
5.16
割安
3.84

Alphio AI による ABT の価格シナリオ

シナリオ価格は本年の最終月次予想レンジです。確率はモデルの固定ウェイト(25 / 50 / 25)であり、保証ではありません。

強

強気

強気 · 25%ABT

$135.45

シナリオ価格

基

基本

基本 · 50%ABT

$133.59

シナリオ価格

弱

弱気

弱気 · 25%ABT

$116.73

シナリオ価格

ABT を保有するクジラ

I

Ingalls & Snyder, LLC

+ を保有ABT

+11.87%

3か月リターン

M

Mizuho Financial Group, Inc.

+ を保有ABT

+9.84%

3か月リターン

C

Cbus Industry Superannuation Fund

+ を保有ABT

+9.20%

3か月リターン

F

Fayez Sarofim & Co., LLC

+ を保有ABT

+8.53%

3か月リターン

M

Millennium Management LLC

+ を保有ABT

+8.36%

3か月リターン

L

Laird Norton Tyee Trust Company

+ を保有ABT

+8.19%

3か月リターン

イベントタイムライン

2026-10-11 (ET)

15:00:00

Freenome Presents Updated SimpleScreen CRC Test Data

2026-10-05 (ET)

09:30:00

Abbott Receives FDA Approval for CardioMEMS HF System Updates

2026-09-30 (ET)

08:30:00

Abbott Launches FDA-Approved SimpleScreen CRC Colorectal Cancer Screening Test

2026-09-24 (ET)

09:30:00

BTIG Analyst Says Grail Cancer Test Received Positive FDA Vote

2026-09-23 (ET)

07:30:00

Abbott Partners with Berry Street for Nutrition Insights

ニュース

ABT のよくある質問 — Alphio AI が回答

Abbott Laboratories is a global healthcare company. The Company’s principal business is the discovery, development, manufacture, and sale of a broad and diversified line of healthcare products. Its segments include Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. Established Pharmaceutical Products segment is engaged in the international sales of a broad line of branded generic pharmaceutical products. Diagnostic Products segment is involved in the worldwide sales of diagnostic systems and tests for blood banks, hospitals, commercial laboratories and alternate-care testing sites. Nutritional Products segment is engaged in the worldwide sales of a broad line of adult and pediatric nutritional products. Medical Devices segment is involved in the worldwide sales of rhythm management, electrophysiology, heart failure, vascular, structural heart, neuromodulation and diabetes care products. It serves people in more than 160 countries. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Abbott Laboratories is a good buy right now due to its current price of $99.60, which is significantly below the analyst price targets ranging from $120 to $127. The forward P/E ratio is 17.094, indicating potential for growth compared to its current valuation. Additionally, the recent product launch of Ensure Max Protein is expected to drive revenue growth, while the RSI of 50.277 suggests the stock is neither overbought nor oversold, making it a favorable entry point.

20 analysts cover ABT: 13 rate it Buy, 7 Hold and 0 Sell. The average price target is 148.11.

コミュニティ

もっと見る ↗
RektEddy2026/9/14

$COST $JD $ABT Many people enter the crypto space chasing quick profits, but real, consistent success is built on knowledge, discipline, and the right guidance. That’s where having a reliable mentor makes all the difference. Craig has played a key role in helping me understand the markets with more clarity and confidence. His approach to trading goes beyond signals, it’s about building structure, managing risk, and staying focused on long-term growth. With his guidance and his YouTube videos, I’ve been able to make smarter decisions, avoid emotional trading, and stay consistent even in volatile conditions. The shift in mindset alone has been a game changer.

もっと見る
登録またはログインして議論に参加

本ページは調査目的であり、投資助言ではありません。モデルは誤ることがあります。過去の実績は将来の成果を保証しません。

取引を始める